Target-4 chimeric antigen receptor T-cell therapy - T-CURX
Latest Information Update: 29 Nov 2022
At a glance
- Originator University of Wuerzburg
- Developer T-CURX
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 18 Nov 2022 Target-4 chimeric antigen receptor T-cell therapy - T-Curx is available for licensing in World as of 18 Nov 2022. https://t-curx.com/company
- 10 Oct 2022 Early research in Solid tumours in Germany (Parenteral) (T-CURX pipeline, November 2022)